Radius presents positive phase I data for investigational drug RAD1901
Radius Health announced data from two ongoing Phase 1 studies of RAD1901, an oral selective estrogen receptor degrader, in patients with estrogen receptor positive breast cancer. As of Oct. 7, 2016, 20 patients have been treated in the RAD1901 Phase IB safety expansion cohort at the 400 mg dose. December 08, 2016